Vision Statement VentriPoint is dedicated to “connecting all the dots”, to improving the diagnosis of heart disease by increasing the accuracy, speed and ease of measuring heart functions using traditional ultrasound and MRI imaging. Message from Dr. George Adams, CEO It is exciting times here at VentriPoint as we have successfully developed a novel way to reconstruct a 3-D image of the heart by identifying anatomical sites in the heart (the dots) and then using an expert database to connect all the dots to form a precise image of the shape and size of the heart. One condition where doctors are particularly challenged is blue-baby syndrome (Tetralogy of Fallot), a congenital heart defect that affects newborn babies. It is very difficult, often impossible, to get accurate measurements of these tiny hearts in order to determine the best way and time to operate on the child to surgically repair the defect. We are gearing up to enable leading pediatric care centers around the world to conduct clinical trials using the VMS™ to demonstrate its universal application to diagnose and monitor many types of heart disease. We already have regulatory approval to sell the system in Europe and Canada. We recently have submitted a response to the US FDA with additional clinical case studies and the agency is evaluating our submission. |
